Luciano Costa, MD, PhD
Enriched profileProfessor of Medicine; Director, Multiple Myeloma Program and Immune Effector Cellular Therapy Program, O'Neal Comprehensive Cancer Center · University of Alabama at Birmingham
Luciano Costa is Professor of Medicine; Director, Multiple Myeloma Program and Immune Effector Cellular Therapy Program, O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham. OpenAlex indexes 601 publications with 17,045 citations (h-index 61); ClinicalTrials.gov lists 5 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Luciano Costa is Professor of Medicine at University of Alabama at Birmingham. The public record shows 601 publications with 17,045 citations (h-index 61), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, CAR-T cell therapy research. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 22 companies, 1 NIH-funded awards (2020–2021).
- Most recent indexed publication: 2026 · Cancer
- Top research focus: Multiple Myeloma Research and Treatments
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 22 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 65 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 212.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
Sponsor: University of Alabama at Birmingham
- Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
Sponsor: University of Alabama at Birmingham
- Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Sponsor: University of Alabama at Birmingham
Industry payments
Updated 27 Aug 2026
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202521 payments$42,219openpaymentsdata.cms.gov ↗
- Regeneron Pharmaceuticals, Inc.Program year20258 payments$22,443openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
26.4%Opioid Agonist14.4%Oxycodone Hcl44%Tramadol Hcl15%Morphine Sulfate Er12%Oxycodone-Acetaminophen9%Fentanyl7%Oxycontin6%Morphine Sulfate3%Tramadol Hcl Er3%Part D<11 patientsGabapentinoids7.6%Gabapentin94%Pregabalin6%Part D<11 patientsDermatology
18.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor18.1%Acyclovir100%Part D≥108 patientsCancer & immunology
14.1%Thalidomide Analog12.5%Revlimid36%Lenalidomide33%Pomalyst31%Part D≥27 patientsBCL-2 Inhibitor1.1%Venclexta100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2020–2021 per NIH RePORTER. The latest:
Congress activity
Updated 27 Aug 2026
138 congress contributions (2004–2025) across AACR, ASCO, ASH, SABCS per OpenAlex. The most recent:
- Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3
ASH Annual Meeting
ASH2025Co-authorLate-breaking
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Targeting BCMA in Patients with Relapsed/Refractory Multiple Myeloma in 1-3 Prior Lines of Therapy.
Blood advances
Article2026
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/luciano-j-costa-88a978ba
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Luciano-J-Costa-47268868
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
uab.edu/reporter/people/achievements/item/9006-aiming-for-a-cure-against-the-odds-uab-cancer-trial-earns-standing-ovation
- YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providerdirectory.uabmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providerdirectory.uabmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →commitmyelomatrials.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →commitmyelomatrials.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providerdirectory.uabmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providerdirectory.uabmedicine.org ↗
Editorial & leadership roles
journal and society appointments- Chair
Scientific Steering Committee, coMMit (Myeloma Trials, Innovated)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →commitmyelomatrials.org ↗ - Director
Multiple Myeloma Program, O'Neal Comprehensive Cancer Center, UAB
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →commitmyelomatrials.org ↗ - Director
Immune Effector Cellular Therapy Program, O'Neal Comprehensive Cancer Center, UAB
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →commitmyelomatrials.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →commitmyelomatrials.org ↗
Secondary affiliations
appointments beyond the home institution- Formerly Associate Professor of Medicine
Medical University of South Carolina; co-chaired Protocol Review Committee, Hollings Cancer Center
2014provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →commitmyelomatrials.org ↗ - Associate Director for Clinical Research
O'Neal Comprehensive Cancer Center at UAB
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →open.spotify.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomacrowd.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Vera Bittner
University of Alabama at Birmingham
Richard Whitley, MD
University of Alabama at Birmingham
David Standaert, MD, PhD
University of Alabama at Birmingham
Erik Roberson
University of Alabama at Birmingham